ASH 2023 | Update on the COMMANDS trial: luspatercept is superior to ESA-based therapy in LR-MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, provides a long-term update on the COMMANDS trial (NCT03682536), which confirms the superior activity of luspatercept versus erythropoiesis-stimulating agent (ESA)-based therapies as first-line treatment for patients with transfusion-dependent, lower-risk myelodysplastic syndromes (LR-MDS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So the COMMANDS trial was a positive study, as you know, in first-line therapy of transfusion-dependent, low-risk MDS. Positive in a way that it showed the superiority of luspatercept versus ESA-based therapy in these patients. Study results have been published also in The Lancet a couple of months ago. So this update now with a longer follow-up, to make a long story short, I would say confirms basically the interim analysis which already got published, not only with regards to the response rates, but also with regards to the durability of response, which was actually longer for luspatercept versus ESA-based therapy...
So the COMMANDS trial was a positive study, as you know, in first-line therapy of transfusion-dependent, low-risk MDS. Positive in a way that it showed the superiority of luspatercept versus ESA-based therapy in these patients. Study results have been published also in The Lancet a couple of months ago. So this update now with a longer follow-up, to make a long story short, I would say confirms basically the interim analysis which already got published, not only with regards to the response rates, but also with regards to the durability of response, which was actually longer for luspatercept versus ESA-based therapy. So I think there is nothing new in a sense that the data look different now. I think the good news is the ASH presentation basically confirms what is already known from the interim analysis.
Read more...
Disclosures
Consultancy: AbbVie, Novartis, Jazz, Bristol Myers Squibb, Servier, Janssen Biotech, Syros, Amgen, Curis, Geron, Silence Therapeutics, Takeda
Honoraria: Novartis, Jazz, Bristol Myers Squibb, Servier, Syros, Celgene, Silence Therapeutics, Takeda
Research Funding: Novartis, Roche, BeiGene, Jazz, Bristol Myers Squibb, Servier, Janssen Biotech, Syros, Merck, Fibrogen, Amgen, Curis, Geron, BMS, Silence Therapeutics, Takeda
Board of Directors/Advisory Committee: MDS Foundation, Bristol Myers Squibb
Travel Support: Bristol Myers Squibb
Medical Writing Support: Bristol Myers Squibb
